Generic Ozempic: Canada Poised to Lead the Way with Lower-Cost Semaglutide

Canada is on the verge of becoming the first Western nation – and potentially the first globally – to introduce generic versions of semaglutide, the active ingredient in the widely used Type 2 diabetes drug Ozempic, and the weight loss medication Wegovy. This development promises increased accessibility and affordability for Canadians managing diabetes and obesity, but also raises questions about potential side effects and the influence of weight-loss focused online culture.

Why Canada First?

The pathway for generic semaglutide in Canada is unique due to the country’s regulatory framework. Health Canada’s policies allow for the introduction of biosimilar drugs – highly similar, but not identical, versions of biologic drugs – through a streamlined approval process. This has accelerated the availability of generic versions of insulin and other biologics, and now, semaglutide is following suit.

Ozempic, Wegovy, and Semaglutide: Understanding the Drugs

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It works by mimicking the effects of GLP-1, a natural hormone that helps regulate blood sugar levels and appetite.

• Ozempic is approved for the treatment of Type 2 diabetes.
• Wegovy is a higher-dose version of semaglutide specifically approved for weight loss, as well as for cardiovascular and metabolic liver disease in Canada.

Impact on Access and Affordability

The introduction of generic semaglutide is expected to significantly lower the cost of the medication, making it more accessible to a wider range of patients. Currently, Wegovy has a list price of $1,349 [1]. Novo Nordisk has recently cut prices for injectable Wegovy and Ozempic to $349 a month for those purchasing directly from the drugmaker, telehealth partners, or retail pharmacies, with introductory pricing of $199 for the first two months for new customers [1]. However, generic options are anticipated to drive prices down even further.

Potential Concerns and Considerations

While increased access is a major benefit, experts have raised concerns about potential side effects and the broader societal impact of readily available weight-loss drugs. Common side effects of semaglutide include nausea, vomiting, diarrhea, and constipation. There are also concerns about the potential for misuse and the influence of a weight-obsessed culture, particularly online.

Competition and Market Dynamics

Several companies are vying to be the first to market with generic semaglutide in Canada. This competition is expected to further drive down prices and increase availability. Novo Nordisk, the manufacturer of Ozempic and Wegovy, is also navigating increased competition from Eli Lilly, whose drugs tirzepatide (Mounjaro and Zepbound) have overtaken semaglutide in U.S. Prescriptions [2]. Novo Nordisk is also facing the loss of exclusivity for Wegovy and Ozempic in certain markets [2].

Recent Developments with Novo Nordisk

Novo Nordisk’s stock recently fell after its next-generation weight loss drug, CagriSema, failed to demonstrate non-inferiority to Eli Lilly’s tirzepatide in clinical trials [2]. This setback adds to the competitive pressures facing the company.

Wegovy Savings Offer

Currently, new patients to the Wegovy Savings Offer and NovoCare Pharmacy pay $199 for each month of 0.25 mg and 0.5 mg, for up to two monthly fills, available through March 31, 2026 [1].

The rise of generic Ozempic in Canada represents a significant shift in the landscape of diabetes and obesity treatment. While offering the potential for greater access and affordability, it also necessitates careful consideration of potential risks and societal implications.